This discrepancy may be attributed to the distinct molecular mechanisms underlying MDS and AML, DDX41 mutations may play a more prominent role in the early stages of myeloid malignancies, such as MDS, rather than in the more genetically complex AML. This evidence concerns the gene DDX41 and acute myeloid leukemia.